Pterostilbene Enhances Cytotoxicity and Chemosensitivity in Human Pancreatic Cancer Cells

Pterostilbene Enhances Cytotoxicity and Chemosensitivity in Human Pancreatic Cancer Cells

Gemcitabine (GEM) drug resistance causes high mortality rates and poor outcomes in pancreatic ductal adenocarcinoma (PDAC) patients. Receptor for advanced glycation end products (RAGE) involvement in the GEM resistance process has been demonstrated. Therefore, finding a safe and effective way to inh...

Full description

Bibliographic Details
Main Authors:	Yi-Hao Hsu, Sheng-Yi Chen, Sheng-Yang Wang, Jer-An Lin, Gow-Chin Yen
Format:	Article
Language:	English
Published:	MDPI AG 2020-05-01
Series:	Biomolecules
Subjects:	apoptosis autophagy chemosensitivity gemcitabine pancreatic ductal adenocarcinoma pterostilbene
Online Access:	https://www.mdpi.com/2218-273X/10/5/709

Similar Items

Chloroquine Potentiates the Anticancer Effect of Pterostilbene on Pancreatic Cancer by Inhibiting Autophagy and Downregulating the RAGE/STAT3 Pathway
by: Rong-Jane Chen, et al.
Published: (2021-11-01)

Girdin Knockdown Increases Gemcitabine Chemosensitivity to Pancreatic Cancer by Modulating Autophagy
by: Sheng Wang, et al.
Published: (2021-03-01)

An Update on Gemcitabine-Based Chemosensitization Strategies in Pancreatic Ductal Adenocarcinoma
by: Tianpeng Zhang, et al.
Published: (2023-12-01)

Lipocalin 2 may be a key factor regulating the chemosensitivity of pancreatic cancer to gemcitabine
by: He Zhang, et al.
Published: (2022-09-01)

Pancreatic Cancer Chemoresistance to Gemcitabine
by: Manoj Amrutkar, et al.
Published: (2017-11-01)

The synergism of Clinacanthus nutans Lindau extracts with gemcitabine: downregulation of anti-apoptotic markers in squamous pancreatic ductal adenocarcinoma
by: Ling-Wei Hii, et al.
Published: (2019-09-01)

Zic family member 5 promotes survival in human pancreatic cancer and cholangiocarcinoma cells
by: Reiko Satow, et al.
Published: (2022-09-01)

Neoadjuvant and Adjuvant Chemotherapy for Pancreatic Adenocarcinoma: Literature Review and Our Experience of NAC-GS
by: Taku Aoki, et al.
Published: (2024-02-01)

ATG4B Inhibitor UAMC-2526 Potentiates the Chemotherapeutic Effect of Gemcitabine in a Panc02 Mouse Model of Pancreatic Ductal Adenocarcinoma
by: Farnaz Sedigheh Takhsha, et al.
Published: (2021-11-01)

Mechanism of Pterostilbene-Induced Cell Death in HT-29 Colon Cancer Cells
by: Joanna Wawszczyk, et al.
Published: (2022-01-01)

Pan-Inhibition of Protein Disulfide Isomerase Caused Cell Death through Disrupting Cellular Proteostasis in Pancreatic Ductal Adenocarcinoma Cells
by: Ching-Sheng Hung, et al.
Published: (2023-11-01)

Ferroptosis: At the Crossroad of Gemcitabine Resistance and Tumorigenesis in Pancreatic Cancer
by: Jianhui Yang, et al.
Published: (2021-10-01)

Organic cation transporter 2 activation enhances sensitivity to oxaliplatin in human pancreatic ductal adenocarcinoma
by: Ching-Feng Chiu, et al.
Published: (2022-09-01)

Therapeutic Aspects and Molecular Targets of Autophagy to Control Pancreatic Cancer Management
by: Md. Ataur Rahman, et al.
Published: (2022-06-01)

Gemcitabine-Based Neoadjuvant Treatment in Borderline Resectable Pancreatic Ductal Adenocarcinoma: A Meta-Analysis of Individual Patient Data
by: Francesco Giovinazzo, et al.
Published: (2020-08-01)

Systematic exploration of the underlying mechanism of gemcitabine resistance in pancreatic adenocarcinoma
by: Kaidong Liu, et al.
Published: (2022-08-01)

Circular RNA Signature Predicts Gemcitabine Resistance of Pancreatic Ductal Adenocarcinoma
by: Feng Shao, et al.
Published: (2018-06-01)

OXCT1 Enhances Gemcitabine Resistance Through NF-κB Pathway in Pancreatic Ductal Adenocarcinoma
by: Jinsheng Ding, et al.
Published: (2021-11-01)

Predictive Value of MUC5AC Signature in Pancreatic Ductal Adenocarcinoma: A Hypothesis Based on Preclinical Evidence
by: Ashish Manne, et al.
Published: (2023-04-01)

Selective Inhibition of Histone Deacetylases 1/2/6 in Combination with Gemcitabine: A Promising Combination for Pancreatic Cancer Therapy
by: Richard S. Laschanzky, et al.
Published: (2019-09-01)

Phosphomimetic Dicer S1016E triggers a switch to glutamine metabolism in gemcitabine-resistant pancreatic cancer
by: Ji Min Park, et al.
Published: (2022-11-01)

Potential Chemopreventive Role of Pterostilbene in Its Modulation of the Apoptosis Pathway
by: Omchit Surien, et al.
Published: (2023-06-01)

A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma
by: Ma Yue, et al.
Published: (2011-03-01)

Clinical benefit of subsequent chemotherapy after drug-induced interstitial lung disease in pancreatic cancer patients: a multicenter retrospective study from Japan
by: Hiroki Irie, et al.
Published: (2023-04-01)

MicroRNA-29c Increases the Chemosensitivity of Pancreatic Cancer Cells by Inhibiting USP22 Mediated Autophagy
by: Limin Huang, et al.
Published: (2018-05-01)

Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma: A Physiopathologic and Pharmacologic Review
by: Tomas Koltai, et al.
Published: (2022-05-01)

Mitophagy in Pancreatic Cancer
by: Yangchun Xie, et al.
Published: (2021-02-01)

Modified gemcitabine plus nab‐paclitaxel regimen in advanced pancreatic ductal adenocarcinoma
by: Jane E. Rogers, et al.
Published: (2020-08-01)

Andrographis Reverses Gemcitabine Resistance through Regulation of ERBB3 and Calcium Signaling Pathway in Pancreatic Ductal Adenocarcinoma
by: Keisuke Okuno, et al.
Published: (2023-01-01)

Vactosertib, TGF-β receptor I inhibitor, augments the sensitization of the anti-cancer activity of gemcitabine in pancreatic cancer
by: Ji Eun Lee, et al.
Published: (2023-06-01)

Pterostilbene-Mediated Inhibition of Cell Proliferation and Cell Death Induction in Amelanotic and Melanotic Melanoma
by: Joanna Wawszczyk, et al.
Published: (2023-01-01)

Autophagy: A Key Player in Pancreatic Cancer Progression and a Potential Drug Target
by: Josef Gillson, et al.
Published: (2022-07-01)

Single-cell RNA sequencing revealed subclonal heterogeneity and gene signatures of gemcitabine sensitivity in pancreatic cancer
by: Zelin Hou, et al.
Published: (2023-06-01)

Enhancement of Anticancer Potential of Pterostilbene Derivative by Chalcone Hybridization
by: Kai-Wei Tang, et al.
Published: (2021-08-01)

Pterostilbene Sensitizes Cisplatin-Resistant Human Bladder Cancer Cells with Oncogenic <i>HRAS</i>
by: Yi-Ting Chen, et al.
Published: (2020-10-01)

Efficacy and Safety of Nab-Paclitaxel Plus S-1 versus Nab-Paclitaxel Plus Gemcitabine for First-Line Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma
by: Zong Y, et al.
Published: (2020-12-01)

NGFR Increases the Chemosensitivity of Colorectal Cancer Cells by Enhancing the Apoptotic and Autophagic Effects of 5-fluorouracil via the Activation of S100A9
by: Hao Chen, et al.
Published: (2021-04-01)

Combination of gemcitabine, nab-paclitaxel, and S-1(GAS) as the first-line treatment for patients with locally advanced or advanced pancreatic ductal adenocarcinoma: study protocol for an open-label, single-arm phase I study
by: Chen Chang, et al.
Published: (2021-05-01)

Differential expression of MAGEA6 toggles autophagy to promote pancreatic cancer progression
by: Yiu Huen Tsang, et al.
Published: (2020-04-01)

Nuclear PLD1 combined with NPM1 induces gemcitabine resistance through tumorigenic IL7R in pancreatic adenocarcinoma
by: Danqi Fu, et al.
Published: (2023-08-01)